Arbutus Biopharma

Company snapshot

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease. We are currently developing imdusiran (AB-729), our proprietary, GalNAc-conjugated, subcutaneously-delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, our proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B virus.

• 13 active pipeline program(s) linked via ClinicalTrials.gov.
• 56 US patent(s) indexed to this assignee profile.
• 13 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Arbutus Biopharma. Not investment advice.

• Peer + 0 momentum

  Vir Biotechnology

  TA overlap score 26.8

• Peer + 0 momentum

  EmeraMed

  TA overlap score 21

Recent activity

Latest pipeline, patent, and corporate events for Arbutus Biopharma.

1. Jun 8, 2026 Clinical update

   AB-729-203 — Phase 2

2. Jun 8, 2026 Clinical update

   AB-101-001 — Phase 1

3. Jun 5, 2026 Clinical update

   TKM-100802 for Injection — Phase 1

4. Jun 5, 2026 Clinical update

   TKM-100201 — Phase 1

5. May 26, 2026 Clinical update

   AB-836 — Phase 1

View all clinical trial activity →

• What is Arbutus Biopharma?

  Arbutus Biopharma is a biotech organization headquartered in Warminster, USA. It trades on NYSE under ticker ABUS. Primary therapeutic focus areas include Chronic Hepatitis b, Hepatitis B, Chronic, Ebola Virus Infection, Chronic Hepatitis, Chronic hepatitis B virus Infection. Nov

• Is Arbutus Biopharma publicly traded?

  Yes. Arbutus Biopharma is listed with ticker ABUS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Arbutus Biopharma develop or market?

  We link 7 drug profile(s) where Arbutus Biopharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/arbutus-biopharma-corp#company-drugs.

• What are the latest developments for Arbutus Biopharma?

  In the last 12 months our linked public records show 13 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Arbutus Biopharma focus on?

  Arbutus Biopharma focuses on Chronic Hepatitis b, Hepatitis B, Chronic, Ebola Virus Infection based on our analysis of their pipeline programs and drug development activities.